Johnson & Johnson : First Quarter 2026 Earnings Infographic

Published: 2026-04-24 15:22:10 ET JNJ

Published on 04/24/2026 at 03:22 pm EDT

Jst @uarter 2026 Results

/£ Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact. The depth and strength of our portfolio and pipeline is unrivaled and our relentless

gJ5.4

billion

Innovative Medicine worldwide reported sales increased 11.2% or 7.4% operationally2. Stelara impacted results2 by -(920) basis points. Primary operational drivers:

$8.6

billion

Worldwide MedTech sales MedTech worldwide reported sales increased 7.7% or 4.6% operationally2 Primary operational drivers:

Joaquin Duato Chairman & Chief Executive Officer

Johnson & Johnson

focus on innovation delivered multiple game-changing approvals this quarter, including ICOTYDE in the U.S. for moderate to severe plaque

psoriasis and VARIPULSE Pro in

@ Tremfya :^..DAY ZALE X CAPLYTAy

CAI?VYKTI"

Electrophysiology Abiomed

Shockwave

Europe. These advancements have the potential to transform patient outcomes and create sustainable, long-term value for

C PYBPEVANT + LAZCLUZE "

amivantamab-vmjW! .lazertinibi

SUSTENNA

Trauma

Wound Closure Contact Lenses & Healing

e»

shareholders. 57

Biosurgery

Surgical Vision

Johnson8iJohnson

For full financial data, non-GAAP reconciliations and c autionary statements, please refer to Johnson & Johnson's earnings release issued on April J4, 2026 avail abIe at https'//www investor jnj com/I'inanciaIs/quarterly results/default aspx ' Non GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the m ost comparable GAAP f inancial measures.

* Non-GAAP measure; excludes the impact of translational currency.

Caution Concerning F arward-Looking Statements: This doc ument contains "forward-looking statements" as defined in the Private Securities Litigation Refo rm Act of 1995 reHarding future aperating and financial performance. You are cautioned not to rely on these Forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainti es that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the "Note to Investors Concerning Forward-Look ing Statements" inc luded in the Johnson & Johnson earnings release issued on April 14, 2026 as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Jo hnson & Johnson does not undertake to update any forward-look ing statement as a result of new information or future events or develop ments.

Disclaimer

Johnson & Johnson published this content on April 24, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 24, 2026 at 19:21 UTC.